HSE National Procedure
HSE National Procedure on Nirsevimab to reduce RSV and associated hospitalisations in Infants
Topic:
Respiratory syncytial virus (rsv),
Immunisation
Document Owner:
Joint Owners: HSE Public Health: National Health Protection, National Clinical Programme for Paediatrics and Neonatology and National Women and Infants Health Programme
National Group:
HSE Public Health: National Health Protection, National Clinical Programme for Paediatrics and Neonatology and National Women and Infants Health Programme
Effective From: 01 August 2025
This Standard Operating Procedure (SOP) has been developed to support Clinicians in the implementation of the respiratory syncytial virus (RSV) Immunisation Pathfinder Programme.
The SOP is for clinicians and seeks to provide direction, information and support for Midwives, Nurses, Pharmacists/Pharmaceutical Technicians, Neonatologists, and Paediatricians working in Maternity Hospitals/ Units, Neonatal Units and Paediatric settings.
This procedure includes information about:
- RSV
- Newborn Infants at greater risk of requiring hospitalisation with RSV
- RSV immunisation and Monoclonal Antibody (mAB)for newborn infants and young children
- Eligibility for 2025 state funded nirsevimab
- Ordering 2025 state funded nirsevimab
- Nirsevimab storage and cold chain management
- Nirsevimab presentation and administration
- Nirsevimab efficacy
- Nirsevimab safety
- Reporting suspected adverse events following immunisation
- Reporting and monitoring administration encounters
- Useful links
- Contact
- References